Posted in: information

Heavy! The latest achievements in the study of broad-spectrum neutralizing antibodies against novel coronavirus! Expert online communication

Not long ago,Jin aishun, Professor, Chongqing Medical UniversityLed the emergency research team of novel coronavirus to find three super antibodies with broad-spectrum neutralizing activity against various mutant strains of novel coronavirus. This latest achievement was published in nature communications, a top international journal.

In the past two years, novel coronavirus variants have emerged continuously, and the neutralizing ability of the antibodies that have been authorized for emergency use is significantly reduced. In this case, the discovery of new broad-spectrum neutralizing antibodies with strong activity will be of great significance to the cure of patients with novel coronavirus and even to the final victory over the COVID-19.

In order to strengthen academic and technical exchanges on the research of broad-spectrum neutralizing active antibodies of the new crown, share research progress, display innovative technologies, and help combat the COVID-19, the instrument information network was specially held“Discovery of broad spectrum neutralizing super antibody against novel coronavirus”We sincerely invite scientific and technological workers from all walks of life sciences, medicine and other circles to participate in the special lecture and contribute scientific and technological strength to the early end of the epidemic.

Scan the code or click to register

https://insevent.instrument.com.cn/t/Y7a

Meeting schedule

Speaker


 Professor Jin aishun(Director, Department of Microbiology and immunology, School of basic medicine, Chongqing Medical University

Jin aishun, Professor, doctoral supervisor, director of Department of Microbiology and immunology and Department of immunology, School of basic medicine, Chongqing Medical University, and director of Chongqing Key Laboratory for basic and Transformation Research of tumor immunity. He studied in Japan, studied molecular oncology at Tokyo Medical and Dental University in Japan and received a doctorate. twoFrom 006 to 2014, he worked in the Department of immunology, Department of medical research, Toyama University and SC world, Japan Researcher of Inc biopharmaceutical company and distinguished researcher of Japan Society for the promotion of Science (JSPS) (2011-2013). He has long been engaged in the development of immunological technologies such as antibody drugs and T cell receptor T cell therapy. Relevant research results have been published in a series of high-level academic journals such as Nature Medicine (20092013). In 2017, he was introduced by Chongqing with high-level talents, hired as a distinguished professor of Bayu scholars, established an immunology innovation research platform (recognized as Chongqing Key Laboratory by the Municipal Bureau of science and technology in 2018), and cooperated with enterprises to carry out research on the transformation of tumor immunotherapy. He has won the title of academic leader of Chongqing discipline and innovation leader of the first talent program of Chongqing. During the outbreak of novel coronavirus in 2020, he led the scientific research team to invest in the research and development of neutralizing antibodies against novel coronavirus. Many technical bottlenecks were overcome in a short period of time, and a technical platform for efficient and rapid screening of neutralizing antibodies was established to screen the high-efficiency neutralizing antibodies of multiple novel coronavirus strains and mutant strains of coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus coronavirus. Relevant achievements are published in nature communication, frontier in immunology, frontier cell and developmental biology, genes & amp; There are more than 10 academic journals such as diseases, and 15 patents have been applied for related achievements, including 3 international patents.

Mr. Zhang Caihui(Applied scientist of saidoris bioanalytical products

Sedolis is an applied scientist of bioanalytical products and has been engaged in protein drug expression, purification and binding activity analysis for nearly ten years. He has rich experience in molecular interaction and troubleshooting. He has assisted many domestic pharmaceutical enterprises to establish drug screening and quality attribute analysis methods based on octet platform.